Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2001, p. 703-712, Vol. 21, No. 3
Division of Basic Sciences, Fred Hutchinson
Cancer Research Center, Seattle, Washington 98109-1024
Received 6 July 2000/Returned for modification 21 August
2000/Accepted 31 October 2000
The Mad family comprises four basic-helix-loop-helix/leucine zipper
proteins, Mad1, Mxi1, Mad3, and Mad4, which heterodimerize with Max and
function as transcriptional repressors. The balance between Myc-Max and
Mad-Max complexes has been postulated to influence cell proliferation
and differentiation. The expression patterns of Mad family genes are
complex, but in general, the induction of most family members is linked
to cell cycle exit and differentiation. The expression pattern of
mad3 is unusual in that mad3 mRNA and protein
were found to be restricted to proliferating cells prior to
differentiation. We show here that during murine development mad3 is specifically expressed in the S phase of the cell
cycle in neuronal progenitor cells that are committed to
differentiation. To investigate mad3 function, we disrupted
the mad3 gene by homologous recombination in mice. No
defect in cell cycle exit and differentiation could be detected in
mad3 homozygous mutant mice. However, upon gamma
irradiation, increased cell death of thymocytes and neural progenitor
cells was observed, implicating mad3 in the regulation of
the cellular response to DNA damage.
The ability of proliferating cells
to exit the cell cycle is crucial to the ordered growth and development
of tissues and organisms, to tissue homeostasis, and to a coordinated
response to stress (46). Failure to exit the cell cycle in
response to differentiation signals and cellular stress, such as DNA
damage, is likely to play a role in oncogenesis (13, 14,
51). The Mad protein family members, as well as the MNT/ROX
proteins, are transcriptional repressors that are thought to antagonize
the functions of the Myc family (c-, N-, L-, and s-Myc) and to be involved in the control of cell cycle exit upon differentiation (20, 25, 26, 36, 38). The Mad proteins are encoded by four
paralogous genes, mad1, mxi1, mad3, and mad4
(3, 20, 27, 60). Like Myc and the more recently
characterized MNT (25, 26, 38), the Mad proteins belong to
a family of basic-helix-loop-helix/leucine zipper (bHLHZ) transcription
factors which require heterodimerization with the stable and widely
expressed adapter protein Max in order to bind the E-box (CACGTG) DNA
recognition site and related sites (4, 7, 18, 27, 60). The
presence of such sequences in synthetic and naturally occurring
promoters permits transactivation by the Myc-Max heterocomplexes in
transient-transfection assays (1, 2, 31). By contrast, in
similar contransfection assays, Mad-Max heterocomplexes act as
transcriptional repressors (4, 6, 27, 60).
Mad repression is mediated through the interaction between a conserved
amino-terminal region (Sin3 interaction domain [SID]) of the Mad
protein with the mSin3A and mSin3B corepressors. These corepressors
exist as multiprotein complexes comprising histone deacetylases (HDACs)
and other factors whose functions are still unclear (6, 19, 28,
32, 49). The function of the HDACs is crucial in mediating
repression, most likely through deacetylation of the lysine residues
within the amino-terminal tails of nucleosomal histones H3 and H4.
Deacetylation leads to increased interaction of the histone tails with
the DNA backbone, forming a repressive chromatin structure
(28). Thus, Mad-Max complexes serve to recruit HDACs,
through association with the mSin3 co repressors, to specific target
genes. This is consistent with the fact that the mSin3 interaction
domain, and hence the ability of Mad to repress transcription, is
required for its biological activities. Indeed, disruption of the
putative amphipathic helix in the SID of Mad1 blocks its ability to
inhibit transformation of mouse embryo fibroblasts by Myc and Ras, to
induce a G1 arrest in the macrophage cell line U937, or to
promote erythroid differentiation of murine erythroleukemia cells
(3-6, 8, 9, 11, 29, 33, 47, 58).
Targeted deletion of mad1 and mxi1 in mice has
provided evidence of their roles in cell cycle exit (15, 16,
50). mad1 mutant mice display an increased
proliferative capacity of late myeloid progenitors (16).
Mice deficient in mxi1 show a more generalized phenotype, as
progressive hyperplasia is detected in tissues such as the spleen and
prostate and degenerative changes are detected in the kidney. Deletion
of mxi1 also increases sensitivity to carcinogens and
results in accelerated tumorigenesis in collaboration with Ink4a
locus deletion. Mouse embryo fibroblasts derived from mxi1-null mice are also more prone to transformation by the
Myc and Ras oncogenes (50). By contrast, mice engineered
to express mad1 under the control of the beta-actin promoter
display multiorgan hypoplasia and a reduced proliferative capacity of
hematopoietic cells and mouse embryo fibroblasts in vitro
(45). Taken together with the results of studies
demonstrating induction of Mad proteins during differentiation, these
results suggest that a balance between the Myc-Max and Mad-Max
complexes regulates cell proliferation and cell cycle exit upon differentiation.
The expression pattern of mad3 remains the most perplexing
of those of the Mad family genes. By Northern blotting mad3
RNA is undetectable in adult tissues with the exception of the testis and the thymus. In these tissues and in mouse embryos, mad3
transcripts were restricted to proliferating cells. In addition, within
a population of proliferating cells, the expression of mad3
was not uniform, suggesting the possibility that mad3
expression is cell cycle regulated (27, 44). In this
paper, we further investigate the expression and function of
mad3 using in situ hybridization and targeted deletion of
the mad3 gene.
Generation of mad3 mutant mice.
The
mad3 cDNA (32) was used to screen a murine
129/Sv genomic library (a kind gift from P. Soriano, Fred Hutchinson
Cancer Research Center); the resulting clone was mapped by restriction analysis, and exon-intron boundaries were sequenced. A gene-targeting vector was prepared as follows: an 845-bp NheI fragment
containing the 5' end of the first coding exon in mad3 and a
5.8-kb BamH1-SacII fragment were cloned in the
NheI and the SacII sites, respectively, of the
vector pPGKneobpAPGKdtabpA (a kind gift of P. Soriano). The positive selection cassette PGKneobpA replaced
a genomic region encompassing the translation initiation codon, the
SID, and the basic helix-loop-helix region. The negative selection
marker, PGKdtabpA, was placed at the 5' end of the 845-bp
short arm (see Fig. 2A). A mock PCR-positive control for the targeted
mad3 locus was made by cloning the 1.6-kb
HindIII-NheI fragment corresponding to the 5'
region of the mad3 locus into the
HindIII-NheI sites of
pPGKneobpAPGKdtabpA.
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.3.703-712.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Targeted Deletion of the S-Phase-Specific Myc Antagonist Mad3
Sensitizes Neuronal and Lymphoid Cells to Radiation-Induced
Apoptosis


![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
RNA preparation and analysis. Total RNA was prepared from embryos at embryonic day 10.5 with TRIzol reagent (Gibco BRL) according to the manufacturer's instructions. Reverse transcription-PCR (RT-PCR) was carried out as described previously (30). The S16 control was amplified with the sense primer 5'-AGGAGCGATTTGCTGGTGTGGA-3' and the antisense primer 5'-GCTACCAGGCCTTTGAGATGGA-3' (35) (20 cycles; primers generated a 102-bp fragment). mad3 was amplified with a primer consisting of 5'-CAGCTGAAGCGGTGCTTAG-3' (forward in the helix-loop-helix coding exon) and 5'-CAGGCCTGAAGAGTCCAAG-3' (reverse in the leucine zipper coding exon; 30 cycles yielded a 263-bp fragment).
In situ hybridization and detection of BrdU. 5-Bromo-2"-deoxyuridine (BrdU) incorporation was done essentially as in described in reference 39. Briefly, 100 µg per kg of body weight was injected intraperitoneally into a pregnant mother. Embryos were harvested 1 h after injection, fixed in 4% paraformaldehyde, paraffin embedded, and sectioned. Sections were then treated for in situ hybridization using 35S-labeled cRNA probes as described previously (27, 44). BrdU was revealed using a monoclonal antibody to BrdU (Becton Dickinson) and detection with Vectastain avidin-biotin-peroxidase complex reagent and diaminobenzidine without nickel (Vector Laboratories) before the slides were dipped into NTB2 emulsion (Kodak). After a 7-day exposure at 4°C, the slides were developed, counterstained with bisbenzidine (Hoechst 33258), and examined under dark-field and epifluorescence illumination with a Zeiss Axioplan microscope.
TUNEL assay. The terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) reaction to detect incorporation of biotinylated dUTP mediated by terminal transferase was carried out on sectioned embryos as described previously (17) except that the slides were microwaved for 2 min in 10 mM sodium citrate, pH 6.0. Biotinylated dUTP was revealed with the Vectastain avidin-biotin-peroxidase complex reagent (Vector) and the diaminobenzidine substrate (Vector) according to the manufacturer's recommendations. Sections were counterstained with Gill's hematoxylin.
Analysis of hematopoiesis and lymphocyte proliferation. Hematopoietic cells from peripheral blood, bone marrow, spleen, and thymus were analyzed by examination of cellular morphology, flow cytometry, and culture in semisolid medium as described previously (16). To analyze cell proliferation of mature T and B lymphocytes, 5 × 104 splenocytes were stimulated in suspension with 20 µg of Escherichia coli lipopolysaccharide (Sigma) per ml or with 2 µg of concanavalin A (Sigma) per ml (in RPMI 1640 medium containing 10% fetal bovine serum [HyClone], 10 mM L-glutamine, and 1 mM melanocyte-stimulating hormone). BrdU was added after 16 h, and cells were harvested after 24, 48, or 72 h. Following BrdU labeling, lymphocytes were fixed with 86% ethanol in phosphate-buffered saline (and stored if necessary at 4°C) and stained with anti-BrdU antibody (Becton Dickinson) and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin G (Cappel) according to the manufacturer's protocols. Following staining with 10 µg of propidium iodide per ml, cells were analyzed on a FACScan cell sorter. The fraction of cells in S phase prior to stimulation with mitogens was determined by staining splenocytes with anti-CD45R or anti-CD8 and anti-CD4 directly conjugated to FITC followed by ethanol fixation, staining with propidium iodide, and analysis on a FACScan cell sorter.
Cell survival analysis.
Primary thymocytes were isolated
from 8-week-old male mad3+/+ and
mad3
/
mice in the 129/Sv inbred background
and cultured in Dulbecco modified Eagle medium supplemented with 250 mM
L-asparagine, 50 mM 2-mercaptoethanol, and 10% fetal
bovine serum (HyClone) as described previously (55). Cell
viability at 24 and 48 h after treatment was determined either by
trypan blue (Gibco) exclusion and counting in a hemocytometer or by
flow cytometric analysis of annexin V-FITC staining (Clontech) using a
FACScan cell sorter (Becton Dickinson). Lymphotoxicity was induced by
gamma irradiation at doses of 100, 200, 500, and 1,000 rads at a rate
of 340 rads/min, by phorbol-12-myristate-13-acetate (PMA) at 2 ng/ml,
by ionomycin at 1 µg/ml, and by dexamethasone at 1 µM.
| |
RESULTS |
|---|
|
|
|---|
mad3 is expressed in the S phase of the cell cycle. In our initial description of mad3 expression (27, 44), we were surprised to find this gene predominantly expressed in cycling cells. In adult mice, mad3 was detected only in the proliferating areas of the thymus and the testis. In the developing embryo, mad3 RNA was detected from day 9.5 to day 12.5 postcoitus (p.c.) especially in the ventricular zone (VZ) of the neuroepithelia, in the progression zone of the limb buds, and in the aortic arches and liver. In all these tissues, mad3 was present in only a fraction of cells, producing a patchwork expression pattern similar to that of genes known to be expressed in specific cell cycle phases (see, for example, reference 54). To investigate this possibility further, we employed in situ hybridization to detect mad3 expression in parallel with immunohistochemistry to measure incorporation of the thymidine analogue BrdU into DNA. We concentrated our analysis on the spinal cord, where neuronal progenitors are generated in the VZ and migrate out to the intermediate zone (IZ) where they differentiate (41). The VZ consists of actively dividing neuronal progenitors. As they differentiate, these precursors exit from the cell cycle and migrate away from the VZ and into the IZ. Differentiation proceeds in a specific sequence with respect to both time and position along the dorsoventral and the rostrocaudal axis.
In the spinal cord before day 9.5 p.c. and in caudal regions between day 10.5 and 12.5 p.c., differentiation had not commenced, as evidenced by the absence of an IZ and the intense BrdU labeling detected all over the transverse section of the VZ (Fig. 1A). At that stage, mad3 expression was nearly undetectable in the neural tube, although it was apparent in the lateral mesenchyme (Fig. 1A and data not shown). By contrast, beginning in the anterior part of the spinal cord at day 10.5 p.c., mad3 expression was intense and restricted to the outermost periphery of the VZ (Fig. 1B). As we had shown previously (27), mad3 expression was absent from the IZ, where mad1 was highly expressed. To determine if cells at the periphery of the VZ were undergoing DNA synthesis, BrdU was injected into pregnant females 1 h before harvesting of embryos. This analysis revealed that BrdU-positive nuclei existed mainly in neural progenitors situated at the periphery of the VZ. These findings are consistent with previous studies demonstrating apical-basal nuclear migration of neuronal progenitors as a function of cell cycle phase (reviewed in references 37 and 56) (Fig. 1C). Double labeling for mad3 expression and BrdU incorporation revealed a striking superposition of the two signals (Fig. 1D and E). Colocalization was not limited to the neural progenitors; it was also observed in neural crest cells migrating from the roof of the neural tube, in the sclerotome, in the limb bud, and in the liver (Fig. 1D, arrows, and data not shown). Because the BrdU pulse was for only 1 h, the coincidence of mad3 signal with BrdU-positive nuclei strongly suggested that mad3 was expressed during the S phase of the cell cycle of neuronal progenitor cells (estimated S phase in neural progenitors is 4 h with a 10-h cell cycle time [see reference 7a]). Yet mad3 was not expressed in all S-phase progenitors, as its transcripts were absent from the embryo before day 9.5 p.c. and in the caudal neural tube, where differentiation had not yet commenced. Thus, mad3 expression would appear to be restricted to neuronal progenitors during the last S phase prior to terminal differentiation. To investigate the function of mad3, we generated a targeted mutation of the murine mad3 gene by homologous recombination in ES cells.
|
Targeted disruption of the murine mad3 gene.
To
inactivate the mad3 gene in mice, we isolated the
genomic fragment encoding MAD3 and determined its exon-intron
structure. The mad3 gene comprises six exons (Fig.
2A), with each of the functional domains
of mad3 (the SID, the basic region, the helix-loop-helix domain, and the leucine zipper) being encoded by separate exons (4-6). The vector used for targeted disruption of the
mad3 gene contained 0.845 kb of genomic DNA
encompassing a segment of exon 1 5' to the translation initiation
codon and 5.8 kb downstream of exon 4 (Fig. 2A). Homologous
recombination between the targeting vector and the mad3
locus replaced the exons encoding the translation initiation codon,
the SID, and the basic region by the positive selection marker
PGKneobpA, inactivating the ability of MAD3 to initiate
translation, repress transcription, and interact with MAX and DNA, thus
creating a functionally null allele. Following standard procedures, the
ES cells were electroporated with the linearized targeting vector and
placed under G418 selection. The surviving colonies were screened by
PCR and Southern blotting of their DNA (Fig. 2B). Correct targeting
occurred in 5% of the surviving colonies. Eight correctly targeted ES
cell clones were injected into mouse blastocysts, yielding founder
chimeric mice, and two ES clones contributed to the germ line in the
chimeras, giving rise to mad3 heterozygote mice. These lines
were derived on the hybrid 129/Sv-C57BL/6J and on the inbred 129/Sv
background, the latter being used in this study. The progeny of mating
between heterozygotes were identified by PCR (Fig. 2C). mad3
homozygote mutants (mad3
/
) were found to be
present at the expected Mendelian ratio
(mad3+/+; 24%; mad3+/
;
48%; mad3
/
, 28% [n = 420] in hybrid 129/Sv × C57BL/6J mice;
mad3+/+; 27%; mad3+/
;
51%; mad3
/
; 22% [n = 377] in inbred 129/Sv mice), indicating no significant embryonic
lethality. mad3
/
mice were viable, appeared
outwardly normal, and showed no obvious differences in size, behavior,
reproductive ability, incidence of neoplasia, or life span compared
with wild-type littermates.
|
mad3-null mice do not display obvious defects in
cellular proliferation or differentiation.
Because the members of
the Myc family of transcription factors are key regulators of cell
proliferation, differentiation, and death, we investigated the
mad3
/
mice for phenotypes related to these
processes, both in vivo and in vitro. In vivo, we failed to find any
significant differences in the number of cells incorporating BrdU in
day 11.5 p.c. embryos or in cells that could be labeled by TUNEL,
a hallmark of apoptosis (data not shown). Special scrutiny was
applied to proliferation and differentiation in the central nervous
system, where mad3 expression was well documented
(references 27 and 44 and this study). Staining for the
neural markers (Delta1, NeuroD1, NeuroD3, Mash1, Jagged2, and Pax3) or
for other members of the Myc family (N-Myc, mad1, mxi1, and
mad4) was identical in mad3+/+ and
mad3
/
mice (data not shown). Because
of abnormalities in the hematopoietic system in
mad1-transgenic (45) and
mad1
/
(16) mice, we carefully
examined the hematopoietic systems of mad3
/
mice. No significant differences were observed between
mad3+/+ and mad3
/
mice in the numbers or types of cells in peripheral blood,
spleen, thymus, or bone marrow. Moreover, there were no differences in the frequency or number of hematopoietic precursor cells of the erythroid or myeloid lineages as determined by in vitro colony assays
of bone marrow cells (data not shown). In vitro, the growth curves and
the cell cycle distribution of mouse embryo fibroblasts prepared from
wild-type and mutant mad3 129/Sv mice did not indicate deregulated proliferation due to the inactivation of mad3
(data not shown).
Increased sensitivity of mad3
/
mice to
gamma irradiation.
Because mad3 and c-Myc were
coexpressed in the thymus (44), where Myc has been shown
elsewhere to influence apoptosis in T lymphocytes
(22, 42, 53, 57), we examined the response of
mad3+/+ and mad3
/
T
cells to apoptotic stimuli. After dissection of thymi
(n = 9 for wild type; n = 9 for
mad3
/
), the thymocytes were placed in
culture and subjected to treatment with different
apoptosis-inducing agents: PMA, ionomycin, dexamethasone, or
gamma irradiation. As determined by trypan blue exclusion, no
significant difference in the ratio between dead and living cells could
be observed between wild-type and mutant cells in medium alone or
supplemented with PMA, ionomycin, or dexamethasone (Fig.
3A). By contrast, in three separate
experiments each employing three mad3+/+ and
three mad3
/
mice, a 10% increase in the
number of dead thymocytes following irradiation was observed
(P < 0.05) (Fig. 3A). This increased cell death in
response to gamma irradiation was observed with doses of 200, 500, and
1,000 rads (Fig. 3B) at 24 or 48 h after treatment (data not
shown). The annexin V assay was used as an independent measure of
apoptotic cell death and gave similar results, i.e., a 10%
increase in annexin V-positive thymocytes following irradiation (Fig.
3C). Interestingly, this effect was specific for mad3
inactivation. No difference in the wild-type rate of death in response
to gamma irradiation was observed in thymocytes isolated from
mad1
/
mice (n = 2) or
transgenic [BAP-mad1] mice (n = 3) (data
not shown). Thymocytes isolated from mice mutant for both the
mad1 and the mad3 genes (n = 3)
behaved similarly to the one from the single
mad3
/
mice (data not shown). The effect of
mad3 loss of function on thymocyte death did not correlate
with an increased rate of T-cell cycling. Stimulation of resting T
cells from mad3
/
mice with concanavalin A
did not induce these cells to enter S phase more rapidly than T cells
from wild-type mice (Fig. 3D). Indeed, there was a trend toward slower
entry of mad3
/
cells into S phase following
stimulation with lectins for both T cells (Fig. 3D) and B cells (data
not shown). Although, as expected, we could readily detect Mad3 protein
in wild-type thymocytes, irradiation did not lead to a significant
increase in Mad3 protein levels. Thus, Mad3 protein is not induced as a
response to damage but may function at normal endogenous levels to
inhibit apoptosis.
|
/
mice displayed this increased
sensitivity to apoptosis, we subjected 10.5-day pregnant
mad3+/
mice that were bred to
mad3+/
males to 200 rads of gamma irradiation.
Embryos were harvested 3 h later, embedded, sectioned, and stained
for TUNEL (17). Very few apoptotic cells could be
observed in both wild-type and mad3 mutant mouse embryos
without irradiation (data not shown). By contrast, as early as 3 h
after irradiation, numerous cells were labeled with TUNEL and had
fragmented nuclei characteristic of apoptosis (Fig.
4). In the neural tube, TUNEL-positive
cells were mainly localized in the periphery of the VZ, in the cells that expressed mad3, and were in the S phase of the cell
cycle when irradiated. TUNEL-positive cellular debris also accumulated in the lumen of the neural tube as previously reported
(40). In these two regions, an increased number of cells
or amount of debris was found in the mad3
/
embryos compared to that in wild-type embryos (Fig. 4). This result
indicates that mad3
/
neural progenitor cells
are also more sensitive to apoptosis induced by gamma
irradiation.
|
| |
DISCUSSION |
|---|
|
|
|---|
We and others have shown previously that the expression of Mad family genes occurs in a sequential manner during cell cycle exit associated with differentiation (3, 10-12, 23, 24, 27, 34, 43, 44, 58). Whereas postmitotic cells in the developing mouse embryo clearly expressed mxi1, mad1, and mad4, mad3 expression could not be detected. In contrast, mad3 transcripts were found exclusively in proliferating cells overlapping with c-Myc or N-Myc expression (27, 43, 44). By combining in situ hybridization and immunological detection of BrdU, we show here that mad3 transcripts were detected exclusively in cells that have incorporated BrdU. Because the embryos used in this study were harvested 1 h after the injection of BrdU, the labeled cells were predominantly in the S phase of the cell cycle. This is consistent with the characteristically patchy expression pattern of mad3 previously observed in proliferating cells and agrees with the protein expression pattern observed for P19 cells (44). The results suggest that expression of mad3 is restricted to the S phase of the cell cycle in many cell types. Interestingly, mad3 was not expressed in all cells in S phase for a given cell lineage. This was best seen in the central nervous system. During the early phase of multiplication of the neural stem cell pool, mad3 was not detected. Instead, mad3 expression was concomitant with the appearance of postmitotic neuron precursors in the IZ. Interestingly, in the adipogenic 3T3L1 cells, mad3 expression correlated also with entry into the S phase of the cell cycle during the proliferative burst preceding terminal differentiation (43). Taken together, these data show that, even though mad3 expression is restricted to proliferating cells, it is closely linked to commitment to cell cycle exit and terminal differentiation.
The only significant phenotype detected in the
mad3-deficient mice was an increased sensitivity to gamma
irradiation. This could be documented in thymocytes ex vivo as well as
in neural progenitor cells in embryo (Fig. 3 and 4). This altered
sensitivity to irradiation was not observed in
mad1-deficient thymocytes or in thymocytes prepared from
mad1-overexpressing transgenic mice (data not shown).
However, in mad1-knockout mice granulocytic progenitor cells
exhibited significantly reduced survival when grown in limiting amounts
of cytokines as well as after treatment with apoptosis-inducing
drugs (15, 16). mad1 overexpression, by
contrast, decreased the proliferative capacity of these cells and
increased their survival when cytokine levels were reduced (45). Interestingly, the effect of mad3 loss on
gamma irradiation-induced cell death was not associated with increased
cell proliferation (Fig. 3D). Myc proteins were also shown previously
to play a role in apoptosis in thymocytes and fibroblasts,
apparently independent of their effects on cell cycle and progression
into G1 (see references 42 and 57 for review). A number of
studies have linked Myc-induced apoptosis to p53 function
(21, 48, 52, 59, 61). Inactivation of p53 indeed prevented
the death of thymocytes in response to a variety of signals including
gamma irradiation (55). Furthermore, decreased
apoptosis in neural progenitors in response to gamma irradiation has been also documented for p53
/
embryos
(40). Since an increased sensitivity to irradiation was
observed for mad3-deficient mice, it is tempting to
speculate that deletion of mad3 altered the transcriptional
balance on Myc-Mad target genes in favor of the activating Myc-Max
complexes, leading in turn to a potentiation of p53-dependent cell
death. Further evidence of genetic interaction between mad3
and p53 during the response to DNA insults awaits the generation and
characterization of mouse double mutants for mad3 and p53.
Targeted mutation of mad3 in mice did not produce any
evident phenotype associated with cell cycle exit and differentiation. This absence of phenotype is in contrast to the recent reports for
mad1- and mxi1-deficient mice (15, 16,
50). As mentioned in the introduction, inactivation of
mad1 deregulated cell cycle exit in granulocyte precursors
while mxi1-deficient mice displayed multiorgan hyperplasia
(16, 50). In mad3-knockout mice, however, no
increase in cell proliferation could be detected in embryos, in T and B
cells, in hematopoietic precursor cells, or in mouse embryo fibroblasts
(Fig. 3D and data not shown). Differentiation of hematopoietic and
neural precursor cells was especially scrutinized, but no precocious or
delayed differentiation could be detected. Redundancy among Mad family
members could be regarded as a potential explanation for the lack of
detectable phenotype in cell cycle and differentiation in the
mad3
/
mice. Indeed, in
mad1-deficient mice we observed ectopic expression of
mxi1 and mad3 in the spleen (16).
However, in mad3 mutant mice, no change in the expression of
any other Mad or Myc genes could be detected. Another possibility is
that MAD3 function is redundant with the function of proteins other
than those within the MAD family. One example is the recent finding of
synthetic effects between mad1-null and
p27KIP1-null mice, suggesting that the proteins encoded by
these two genes may function in parallel to influence differentiation
(G. A. McArthur et al., submitted for publication). In this
regard, it is conceivable that MAD3 function is redundant with that of proteins involved in cell cycle regulation or in apoptosis.
These possibilities can be further explored using multiple deletions of
Mad family genes as well as of other genes involved in regulation of differentiation.
| |
ACKNOWLEDGMENTS |
|---|
We are indebted to Leni Sue Carlos and Pei Feng Cheng for technical assistance and to Keesook Lee for expert work in gene targeting. We are grateful to Philippe Soriano for advice and reagents. We are also thankful to to George Sale and the pathology service and to Barbara Johnston and the technicians of the animal facility.
This work was supported by grants CA57138 and HL54881 to R.N.E., a fellowship from the Damon Runyon-Walter Winchell Foundation (DRG-076) and a Special Fellowship of the Leukemia Society of America to G.A.M., and an NIH Mentored Clinical Investigator Award (K08 AJ01445) to B.M.I. R.N.E. is a Research Professor of the American Cancer Society.
| |
FOOTNOTES |
|---|
*
Corresponding author. Mailing address: Division of
Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview
Ave. North
Mailstop A2-025, P.O. Box 19024, Seattle, WA
98109-1024. Phone: (206) 667-4445. Fax: (206) 667-6522. E-mail:
eisenman{at}fred.fhcrc.org.
Present address: AstraZeneca Transgenic Center, S-431 83 Mölndal, Sweden.
Present address: Peter MacCallum Cancer Institute, Division of
Haematology and Medical Oncology, Victoria 8006, Australia.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Amati, B., S. Dalton, M. W. Brooks, T. D. Littlewood, G. I. Evan, and H. Land. 1992. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 359:423-426[CrossRef][Medline]. |
| 2. |
Amin, C.,
A. J. Wagner, and N. Hay.
1993.
Sequence-specific transcriptional activation by Myc and repression by Max.
Mol. Cell. Biol.
13:383-390 |
| 3. |
Ayer, D. E., and R. N. Eisenman.
1993.
A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation.
Genes Dev.
7:2110-2119 |
| 4. | Ayer, D. E., L. Kretzner, and R. N. Eisenman. 1993. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72:211-222[CrossRef][Medline]. |
| 5. | Ayer, D. E., C. D. Laherty, Q. A. Lawrence, A. P. Armstrong, and R. N. Eisenman. 1996. Mad proteins contain a dominant transcription repression domain. Mol. Cell. Biol. 16:5772-5781[Abstract]. |
| 6. | Ayer, D. E., Q. A. Lawrence, and R. N. Eisenman. 1995. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80:767-776[CrossRef][Medline]. |
| 7. |
Blackwood, E. M., and R. N. Eisenman.
1991.
Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.
Science
251:1211-1217 |
| 7a. | Caviness, V. S. J., T. Takahashi, and R. S. Nowakowski. 1995. Numbers, time and neocortical neurogenesis: a general developmental and evolutionary model. Trends Neurosci. 18:379-383[CrossRef][Medline]. |
| 8. | Cerni, C., K. Bousset, C. Seelos, H. Burkhardt, M. Henriksson, and B. Luscher. 1995. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins. Oncogene 11:587-596[Medline]. |
| 9. | Chen, J., T. Willingham, L. R. Margraf, N. Schreiber-Agus, R. A. DePinho, and P. D. Nisen. 1995. Effects of the Myc oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Nat. Med. 1:638-643[CrossRef][Medline]. |
| 10. |
Chin, L.,
N. Schreiber-Agus,
I. Pellicer,
K. Chen,
H. W. Lee,
M. Dudast,
C. Cordon-Cardo, and R. A. DePinho.
1995.
Contrasting roles for Myc and Mad proteins in cellular growth and differentiation.
Proc. Natl. Acad. Sci. USA
92:8488-8492 |
| 11. | Cultraro, C. M., T. Bino, and S. Segal. 1997. Function of the c-Myc antagonist mad1 during a molecular switch from proliferation to differentiation. Mol. Cell. Biol. 17:2353-2359[Abstract]. |
| 12. | Delgado, M. D., A. Lerga, M. Canelles, M. T. Gomez-Casares, and J. Leon. 1995. Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells. Oncogene 10:1659-1665[Medline]. |
| 13. | Fero, M. L., E. Randel, K. E. Gurley, J. M. Roberts, and C. J. Kemp. 1998. The murine gene P27(Kip1) is haplo-insufficient for tumour suppression. Nature 396:177-180[CrossRef][Medline]. |
| 14. | Fero, M. L., M. Rivkin, M. Tasch, P. Porter, C. E. Carow, E. Firpo, K. Polyak, L. H. Tsai, V. Broudy, R. M. Perlmutter, K. Kaushansky, and J. M. Roberts. 1996. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85:733-744[CrossRef][Medline]. |
| 15. | Foley, K. P., and R. N. Eisenman. 1999. Two MAD tails: what the recent knockouts of mad1 and mxi1 tell us about the Myc/MAX/MAD network. Biochim. Biophys. Acta 1423:M37-M47[Medline]. |
| 16. | Foley, K. P., G. A. McArthur, C. Queva, P. J. Hurlin, P. Soriano, and R. N. Eisenman. 1998. Targeted disruption of the Myc antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. EMBO J. 17:774-785[CrossRef][Medline]. |
| 17. |
Gavrieli, Y.,
Y. Sherman, and S. A. Ben-Sasson.
1992.
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
J. Cell Biol.
119:493-501 |
| 18. | Grandori, C., and R. N. Eisenman. 1997. Myc target genes. Trends Biochem. Sci. 22:177-181[CrossRef][Medline]. |
| 19. | Hassig, C. A., T. C. Fleischer, A. N. Billin, S. L. Schreiber, and D. E. Ayer. 1997. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89:341-347[CrossRef][Medline]. |
| 20. | Henriksson, M., and B. Luscher. 1996. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 68:109-182[Medline]. |
| 21. |
Hermeking, H., and D. Eick.
1994.
Mediation of c-Myc-induced apoptosis by p53.
Science
265:2091-2093 |
| 22. |
Hueber, A. O.,
M. Zornig,
D. Lyon,
T. Suda,
S. Nagata, and G. I. Evan.
1997.
Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis.
Science
278:1305-1309 |
| 23. |
Hurlin, P. J.,
D. E. Ayer,
C. Grandori, and R. N. Eisenman.
1994.
The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.
Cold Spring Harbor Symp. Quant. Biol.
59:109-116 |
| 24. | Hurlin, P. J., K. P. Foley, D. E. Ayer, R. N. Eisenman, D. Hanahan, and J. M. Arbeit. 1995. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Oncogene 11:2487-2501[Medline]. |
| 25. |
Hurlin, P. J.,
C. Queva, and R. N. Eisenman.
1997.
Mnt, a novel Max-interacting protein, is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
Genes Dev.
11:44-58 |
| 26. | Hurlin, P. J., C. Queva, and R. N. Eisenman. 1997. Mnt: a novel Max-interacting protein and Myc antagonist. Curr. Top. Microbiol. Immunol. 224:115-121[Medline]. |
| 27. | Hurlin, P. J., C. Queva, P. J. Koskinen, E. Steingrimsson, D. E. Ayer, N. G. Copeland, N. A. Jenkins, and R. N. Eisenman. 1995. mad3 and mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J. 14:5646-5659[Medline]. |
| 28. | Knoepfler, P. S., and R. N. Eisenman. 1999. Sin meets NuRD and other tails of repression. Cell 99:447-450[CrossRef][Medline]. |
| 29. | Koskinen, P. J., D. E. Ayer, and R. N. Eisenman. 1995. Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions. Cell Growth Differ. 6:623-629[Abstract]. |
| 30. | Kraut, N., L. Snider, C. M. Chen, S. J. Tapscott, and M. Groudine. 1998. Requirement of the mouse I-mfa gene for placental development and skeletal patterning. EMBO J. 17:6276-6288[CrossRef][Medline]. |
| 31. | Kretzner, L., E. M. Blackwood, and R. N. Eisenman. 1992. Myc and Max proteins possess distinct transcriptional activities. Nature 359:426-429[CrossRef][Medline]. |
| 32. | Laherty, C. D., W. M. Yang, J. M. Sun, J. R. Davie, E. Seto, and R. N. Eisenman. 1997. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89:349-356[CrossRef][Medline]. |
| 33. |
Lahoz, E. G.,
L. Xu,
N. Schreiber-Agus, and R. A. DePinho.
1994.
Suppression of myc, but not E1a, transformation activity by Max-associated proteins, Mad and mxi1.
Proc. Natl. Acad. Sci. USA
91:5503-5507 |
| 34. | Larsson, L. G., M. Pettersson, F. Oberg, K. Nilsson, and B. Luscher. 1994. Expression of mad, mxi1, max and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc. Oncogene 9:1247-1252[Medline]. |
| 35. | Leonard, M. W., K. C. Lim, and J. D. Engel. 1993. Expression of the chicken GATA factor family during early erythroid development and differentiation. Development 119:519-531[Abstract]. |
| 36. | McArthur, G. A., C. D. Laherty, C. Queva, P. J. Hurlin, L. Loo, L. James, C. Grandori, P. Gallant, Y. Shiio, W. C. Hokanson, A. C. Bush, P. F. Cheng, Q. Lawrence, B. Pulverer, P. Koskinen, K. P. Foley, D. E. Ayer, and R. N. Eisenman. 1998. The Mad protein family links transcriptional repression to cell differentiation. Cold Spring Harbor Symp. Quant. Biol. 63:423-433[CrossRef][Medline]. |
| 37. | McConnell, S. K. 1995. Constructing the cerebral cortex: neurogenesis and fate determination. Neuron 15:761-768[CrossRef][Medline]. |
| 38. | Meroni, G., A. Reymond, M. Alcalay, G. Borsani, A. Tanigami, R. Tonlorenzi, C. L. Nigro, S. Messali, M. Zollo, D. H. Ledbetter, R. Brent, A. Ballabio, and R. Carrozzo. 1997. Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor EMBO J. 16:2892-2906[CrossRef][Medline]. (Erratum, 16:6055.) |
| 39. | Miller, M. W., and R. S. Nowakowski. 1988. Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system. Brain Res. 457:44-52[CrossRef][Medline]. |
| 40. | Norimura, T., S. Nomoto, M. Katsuki, Y. Gondo, and S. Kondo. 1996. p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nat. Med. 2:577-580[CrossRef][Medline]. |
| 41. | Nornes, H. O., and M. Carry. 1978. Neurogenesis in spinal cord of mouse: an autoradiographic analysis. Brain Res. 159:1-6[CrossRef][Medline]. |
| 42. | Prendergast, G. C. 1999. Mechanisms of apoptosis by c-Myc. Oncogene 18:2967-2987[CrossRef][Medline]. |
| 43. | Pulverer, B., A. Sommer, G. A. McArthur, R. N. E. Eisenman, and B. Luscher. 2000. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed mad1. J. Cell. Physiol. 183:399-410[CrossRef][Medline]. |
| 44. | Quéva, C., P. J. Hurlin, K. P. Foley, and R. N. Eisenman. 1998. Sequential expression of the MAD family of transcriptional repressors during differentiation and development. Oncogene 16:967-977[CrossRef][Medline]. |
| 45. |
Queva, C.,
G. A. McArthur,
L. S. Ramos, and R. N. Eisenman.
1999.
Dwarfism and dysregulated proliferation in mice overexpressing the Myc antagonist MAD1.
Cell Growth Differ.
10:785-796 |
| 46. | Raff, M. C. 1996. Size control: the regulation of cell numbers in animal development. Cell 86:173-175[CrossRef][Medline]. |
| 47. | Roussel, M. F., R. A. Ashmun, C. J. Sherr, R. N. Eisenman, and D. E. Ayer. 1996. Inhibition of cell proliferation by the mad1 transcriptional repressor. Mol. Cell. Biol. 16:2796-2801[Abstract]. |
| 48. | Rupnow, B. A., R. M. Alarcon, A. J. Giaccia, and S. J. Knox. 1998. p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts. Cell Death Differ. 5:141-147[CrossRef][Medline]. |
| 49. | Schreiber-Agus, N., L. Chin, K. Chen, R. Torres, G. Rao, P. Guida, A. I. Skoultchi, and R. A. DePinho. 1995. An amino-terminal domain of mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80:777-786[CrossRef][Medline]. |
| 50. | Schreiber-Agus, N., Y. Meng, T. Hoang, H. Hou, Jr., K. Chen, R. Greenberg, C. Cordon-Cardo, H.-W. Lee, and R. A. DePinho. 1998. Role of mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 393:483-487[CrossRef][Medline]. |
| 51. |
Sherr, C. J.
1996.
Cancer cell cycles.
Science
274:1672-1677 |
| 52. |
Sherr, C. J.
1998.
Tumor surveillance via the ARF-p53 pathway.
Genes Dev.
12:2984-2991 |
| 53. |
Shi, Y.,
J. M. Glynn,
L. J. Guilbert,
T. G. Cotter,
R. P. Bissonnette, and D. R. Green.
1992.
Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas.
Science
257:212-214 |
| 54. | Sitzmann, J., K. Noben-Trauth, H. Kamano, and K. H. Klempnauer. 1996. Expression of B-Myb during mouse embryogenesis. Oncogene 12:1889-1894[Medline]. |
| 55. | Strasser, A., A. W. Harris, T. Jacks, and S. Cory. 1994. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329-339[CrossRef][Medline]. |
| 56. |
Takahashi, T.,
R. S. Nowakowski, and V. S. Caviness, Jr.
1996.
Interkinetic and migratory behavior of a cohort of neocortical neurons arising in the early embryonic murine cerebral wall.
J. Neurosci.
16:5762-5776 |
| 57. | Thompson, E. B. 1998. The many roles of c-Myc in apoptosis. Annu. Rev. Physiol. 60:575-600[CrossRef][Medline]. |
| 58. |
Västrik, I.,
A. Kaipainen,
T.-L. Pentillä,
A. Lymboussakis,
R. Alitalo,
M. Parvinen, and K. Alitalo.
1995.
Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro.
J. Cell Biol.
128:1197-1208 |
| 59. |
Wagner, A. J.,
J. M. Kokontis, and N. Hay.
1994.
Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.
Genes Dev.
8:2817-2830 |
| 60. | Zervos, A. S., J. Gyuris, and R. Brent. 1993. mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72:223-232[CrossRef][Medline]. (Erratum, 79:389, 1994.) |
| 61. |
Zindy, F.,
C. M. Eischen,
D. H. Randle,
T. Kamijo,
J. L. Cleveland,
C. J. Sherr, and M. F. Roussel.
1998.
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.
Genes Dev.
12:2424-2433 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»